The 10 analysts offering 12-month price forecasts for PTC Therapeutics Inc have a median target of 62.50, with a high estimate of 75.00 and a low estimate of 49.00. The median estimate represents a +32.58% increase from the last price of 47.14.
The current consensus among 11 polled investment analysts is to Hold stock in PTC Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$1.58
Reporting Date May 06
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.